- Home
- SLG vs PTCT Comparison
SLG vs PTCT Comparison
Compare SLG & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- PTCT
- Stock Information
- Founded
- SLG 1980
- PTCT 1998
- Country
- SLG United States
- PTCT United States
- Employees
- SLG N/A
- PTCT N/A
- Industry
- SLG Real Estate Investment Trusts
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- PTCT Health Care
- Exchange
- SLG Nasdaq
- PTCT Nasdaq
- Market Cap
- SLG 4.0B
- PTCT 5.3B
- IPO Year
- SLG 1997
- PTCT 2013
- Fundamental
- Price
- SLG $51.85
- PTCT $71.12
- Analyst Decision
- SLG Buy
- PTCT Buy
- Analyst Count
- SLG 15
- PTCT 17
- Target Price
- SLG $63.00
- PTCT $73.24
- AVG Volume (30 Days)
- SLG 1.4M
- PTCT 1.1M
- Earning Date
- SLG 10-15-2025
- PTCT 11-04-2025
- Dividend Yield
- SLG 6.15%
- PTCT N/A
- EPS Growth
- SLG N/A
- PTCT N/A
- EPS
- SLG N/A
- PTCT 8.94
- Revenue
- SLG $661,814,000.00
- PTCT $1,779,150,000.00
- Revenue This Year
- SLG N/A
- PTCT $119.02
- Revenue Next Year
- SLG $9.79
- PTCT N/A
- P/E Ratio
- SLG N/A
- PTCT $8.03
- Revenue Growth
- SLG N/A
- PTCT 97.54
- 52 Week Low
- SLG $45.15
- PTCT $35.95
- 52 Week High
- SLG $82.81
- PTCT $73.98
- Technical
- Relative Strength Index (RSI)
- SLG 42.10
- PTCT 68.58
- Support Level
- SLG $49.20
- PTCT $66.10
- Resistance Level
- SLG $51.75
- PTCT $73.98
- Average True Range (ATR)
- SLG 1.62
- PTCT 2.58
- MACD
- SLG 0.07
- PTCT 0.07
- Stochastic Oscillator
- SLG 58.65
- PTCT 64.93
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.